An important mono- and adjunct therapy for diabetes patients now has generic competition in Canada, where an estimated 10% of the population are said to have been diagnosed with type 1 or type 2 diabetes.

Alvotech has swiftly advanced in Japan and Canada, as part of its mission to introduce its pipeline of biosimilars across the globe.

Hot on the heels of rival Celltrion, Jamp and partner Alvotech have now launched their own higher-strength adalimumab biosimilar in Canada, setting up a showdown between their Simlandi version and Celltrion’s Yuflyma.

Canada’s Jamp Pharma has delivered on plans to create a new dedicated biosimilars division as it prepares to launch the recently-approved higher-strength adalimumab biosimilar on which it has partnered with Alvotech.